We expect investors to focus on
Anavex Life Sciences’ ( AVXL Quick Quote AVXL - Free Report) development efforts for its pipeline candidates, when it reports third-quarter fiscal 2021 earnings results.
The company has a mixed surprise history with its earnings having surpassed expectations in two of the trailing four quarters, missing the mark in one and meeting the same in another. The average earnings surprise was 8.86%. In the last reported quarter, Anavex reported breakeven earnings.
Anavex’s stock has rallied 289.6% this year so far against the
industry’s decline of 1.9%. Image Source: Zacks Investment Research
Let’s see how things have shaped up for this announcement.
Factors to Consider
With no approved products in its portfolio, Avanex does not generate any revenues.
Hence, pipeline development should remain the key focus for investors during its upcoming quarterly release, especially updates on its lead investigational compound ANAVEX2-73 (blarcamesine). The candidate is being evaluated for the treatment of Alzheimer’s disease (AD).
Recently, ANAVEX2-73 successfully completed a phase II study for Alzheimer’s disease, a phase II proof-of-concept study on Parkinson’s disease dementia and a phase II study in adult patients with Rett syndrome.
Earlier, management announced that the Independent Data Safety Monitoring Board (DSMB) completed the pre-planned review of the interim safety data for the company’s above-mentioned ongoing studies on the lead drug. Upon review, the DSMB recommended to continue the studies without modification.
In June 2021, the company announced that it exceeded its enrollment target for the ANAVEX2-73 phase IIb/III study on Alzheimer’s disease. It expects to announce top-line results from the same by mid-2022.
Management also announced ANAVEX2-73’s label expansion by a US patent to treat a range of cardiac dysfunctions.
The company recently reported that treatment with ANAVEX2-73 resulted in a significant increase in the expression of the SIGMAR1 mRNA biomarker that substantially correlated with improvements in the primary and secondary clinical efficacy endpoints CoA and MDS-UPDRS Part III and MDS-UPDRS Total.
Another investigational drug ANAVEX3-71 is in phase I study for frontotemporal dementia. The candidate also exhibited disease-modifying activity against the major hallmarks of AD in pre-clinical studies.
An update on all these evaluations is expected on the third-quarter conference call. R&D costs of the company are expected to have risen in the quarter to be reported.
Our proven model does not conclusively predict an earnings beat for Anavex this time around. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. Earnings ESP: Anavex has an Earnings ESP is 0.00%. Both the Zacks Consensus Estimate and the Most Accurate Estimate stand at a loss of 13 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Anavex currently carries a Zacks Rank #3. Stocks to Consider
Here are some biotech stocks that have the right combination of elements to beat on earnings this season:
Corvus Pharmaceuticals ( CRVS Quick Quote CRVS - Free Report) has an Earnings ESP of +14.29% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here . CytomX Therapeutics ( CTMX Quick Quote CTMX - Free Report) has an Earnings ESP of +12.66% and a Zacks Rank #2, currently. Evelo Biosciences ( EVLO Quick Quote EVLO - Free Report) has an Earnings ESP of +16.15% and a Zacks Rank of 2, presently